Dr. Bruce received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Aspreva Pharmaceuticals.
Systemic Lupus Erythematosus
Accumulation of coronary artery disease risk factors over three years: Data from an international inception cohort
Version of Record online: 31 JAN 2008
Copyright © 2008 by the American College of Rheumatology
Arthritis Care & Research
Volume 59, Issue 2, pages 176–180, 15 February 2008
How to Cite
Urowitz, M. B., Gladman, D., Ibañez, D., Fortin, P., Sanchez-Guerrero, J., Bae, S., Clarke, A., Bernatsky, S., Gordon, C., Hanly, J., Wallace, D., Isenberg, D., Ginzler, E., Merrill, J., Alarcón, G. S., Steinsson, K., Petri, M., Dooley, M. A., Bruce, I., Manzi, S., Khamashta, M., Ramsey-Goldman, R., Zoma, A., Sturfelt, G., Nived, O., Maddison, P., Font, J., van Vollenhoven, R., Aranow, C., Kalunian, K., Stoll, T. and Systemic lupus international collaborating clinics (2008), Accumulation of coronary artery disease risk factors over three years: Data from an international inception cohort. Arthritis & Rheumatism, 59: 176–180. doi: 10.1002/art.23353
- Issue online: 31 JAN 2008
- Version of Record online: 31 JAN 2008
- Manuscript Accepted: 20 AUG 2007
- Manuscript Received: 20 FEB 2007
- Canadian Institutes of Health Research
- Lupus Foundation of Ontario, Lupus UK, Lupus Ontario
- Conn Smythe Foundation, Tolfo Family
- Lupus Foundation of America State Chapters of New Jersey
- Long Island-Queens, Western New York, and Nashville
To examine the accumulation of risk factors over 3 years in a multicenter, international inception cohort of patients with systemic lupus erythematosus (SLE).
The Systemic Lupus International Collaborating Clinics registry for atherosclerosis comprises 27 centers from 11 countries. An inception cohort of 935 patients with SLE was assembled, according to a standardized protocol, from 2000 to 2006 to study risk factors for atherosclerosis. Both classic and other coronary artery disease (CAD) risk factors were collected at entry and through 3 years of followup. Therapy was documented over the 3 years. The Framingham 10-year risk factor profile was calculated for each patient at year 1 and year 3.
A total of 278 patients from the inception cohort were followed for 3 years and constituted the population for this study. At enrollment a substantial number of patients already demonstrated several risk factors for CAD, both classic and other. All risk factors increased from enrollment over the 3 years of followup. Treatment of hypertension and hypercholesterolemia also increased over 3 years, but less so for hypercholesterolemia. The Framingham 10-year CAD risk profile was higher in men than in women both at entry and at 3 years, and remained unchanged over the 3 years. Corticosteroid use increased only slightly over 3 years, but use of antimalarials and immunosuppressive agents increased to a greater extent.
Patients with SLE should be monitored for CAD risk factors from the time of diagnosis and appropriate treatment should be instituted early.